Our initial investigative mono was design with 1 week overlap , when HAART was continue one more week together with Leronlimab , than HAART was stopped.

This was base on wrong half life , 3.5 days of Leronlimab , now we know it is about 10 days...
The differences between doses and half life are so small that when one read medical book , they mostly showing one half life for medicine with different doses...

Imo , now when we have Receptor Occupancy test , all patients should not be treated with 700 mg , but according to this test..

According to information in one PR , in pivotal mono they be using 4 weeks overlap with HAART .

According to Dr Patterson Receptor Occupancy Test is very accurate , no reason to expose patients to higher dose of any medicine then needed...in any circumstances ...

And the most important , let just start ...and lets approve asap.!!!!!!


All IMO as always ..